Omics Approaches in Breast Cancer

Dr Debmalya Barh is the founder of Institute of Integrative Omics and Applied Biotechnology (IIOAB) at Nonakuri, Tamluk, West Bengal, India. His core competencies include bioinformatics, genome, genomics and proteomics, cell signaling, integrative omics based marker and target discovery, cancer pharmacogenomics, personalized medicine, cardiovascular and infectious diseases. He has been a consultant for three top healthcare and diagnostic companies in USA. He is the reviewer/editorial board member of many journals like CMAJ, Molecular Medicine, Bioinformatics, BMC Genomics, BMC Systems Biology, Journal of Medical Informatics, Current Oncology, Gene Therapy, J. Cardiovascular Dis Res, J Integrated Omics, AIOAB. He has several scientific publications including genome sequences, journal articles, book chapters and reference books.

Omics Technologies Applied in Breast Cancer Research.- Omics of Hereditary Breast Cancer.-Oncogenes and Tumor Supressor Genes as a Biomarker in Breast Cancer.-Breast Cancer Genomics.-Epigenomics of Breast Cancer.-Nutrigenomics in Breast Cancer.-Long Non-coding RNAs in Breast Cancer: Implications for Pathogenesis, Diagnosis and Therapy.-Breast Cancer MicroRNAs: Clinical Biomarkers for the Diagnosis and Treatment Strategies.-Breast Cancer Proteomics.-Metabolomics in Breast Cancer.-Lipidomics in Breast Cancer.-Breast Cancer Stem Cells and Cellomics.-Omics of Male Breast Cancer.-Omics of Chemoresistant and Metastatic Breast Cancer.-Animal Models of Breast Cancer.-In Silico Disease Models of Breast Cancer.- Systems Biology and Integrative Omics in Breast Cancer.- Gynecologic Considerations for Women with Breast Cancer.-Imaging Technologies and Applications in Early Diagnosis and Prognosis for Breast Cancer.- Breast Cancer Biomarkers for Risk Assessment, Screening, Detection, Diagnosis, and Prognosis.- Breast Circulating Tumor Cells: Potential Biomarkers for Breast Cancer Diagnosis and Prognosis Evaluation.-Molecular Diagnosis Of Metastasizing Breast Cancer Based Upon Liquid Biopsy.- Exhaled Volatile Organic Compounds as Non-Invasive Markers in Breast Cancer.- Breast Cancer Therapy–Classical Therapy, Drug Targets and Targeted Therapy.- Pharmacogenomics–Pharmacoepigenomics of Breast Cancer Therapy: Clinical Implications.- Breast Cancer Gene Therapy.- Clinical Trial Endpoints in Breast Cancer.